Armata Pharmaceuticals, Inc. 10-Qquarter ended 2026-09-30

Executive Summary

Armata Pharmaceuticals develops bacteriophage therapies for patients with difficult-to-treat bacterial infections and currently earns revenue from grants, not product sales. Its priority is advancing AP-SA02 into Phase 3 for complicated bloodstream infections caused by Staphylococcus aureus, supported by encouraging early clinical results and FDA feedback. Q3 showed progress in manufacturing readiness and government reimbursement, but reported profitability came from a noncash loan-valuation gain rather than an economically self-sustaining business. The opportunity is a new treatment alongside antibiotics; the immediate constraint is financing, with $18.3M in cash and management reporting substantial doubt about Armata’s ability to continue as a going concern.

What's Happening in the Business

AP-SA02 is moving from early clinical evidence toward a larger test. In the Phase 1b/2a diSArm study, investigator-assessed clinical response at day 12 was 88% with AP-SA02 plus best available antibiotics vs 58% with antibiotics plus placebo. The study was small, with missing assessments, so these results are encouraging rather than definitive.

FDA’s 1/2026 End-of-Phase 2 response supported advancing AP-SA02. Management expects Phase 3 initiation in H2 2026, subject to FDA concurrence, with ≈550 adults and clinical response at day 70 as the proposed primary endpoint. Engineering runs and Q3 clinical-material production and vialing were completed. A $3.7M increase brought the cumulative MTEC government award to $32.4M, extending support through 12/31/2026 for development and Phase 3 preparation and execution; this is cost reimbursement, not commercial demand.

AP-PA02 presents a less straightforward development decision. Its Phase 2 Tailwind study in non-cystic-fibrosis bronchiectasis did not meet the primary endpoint in either separately analyzed cohort. A post-hoc pooled analysis suggested lower bacterial counts, but does not replace the unsuccessful prespecified analyses. Further development depends on additional funding.

Key Financial Highlights

• Loan revaluation: Noncash gains were $69.6M in Q3 and $59.6M over 9M. The valuation is sensitive to Armata’s share price and assumes full conversion into equity; a falling estimated liability produces income even though the development business remains loss-making.
• Development costs: 9M R&D rose 16% to $20.5M. Clinical-trial costs fell to ≈$0.2M from $1.8M after Phase 2 completion, while manufacturing-related external costs rose 67% to $3.10M. Company-wide stock-based compensation increased to $6.68M from $1.98M, helping explain higher personnel expenses without equivalent cash spending.
• Cash use: 9M OCF was $(20.0)M vs $(19.1)M, despite reported net income. The noncash loan gain explains the main earnings–cash divergence; financing inflows of $28.5M replenished liquidity.
• Financing burden: Term loans totaled $110M principal, generally at 14% stated interest, alongside a $30.0M-principal convertible loan. Earlier loans mature on 6/1/2027; later term loans mature on 1/11/2029. Amendments were treated as a troubled debt restructuring because Armata was in financial difficulty and received lender concessions.

Risk Assessment

• Going concern: Management says available cash cannot fund the following 12 months, and financing plans are not considered probable; failure could force development cuts or surrender of product rights.
• Clinical uncertainty: AP-SA02’s small early trial may not predict Phase 3 success, while AP-PA02’s failed prespecified analyses weaken the evidence supporting further investment.
• Secured debt and dilution: Loans are secured by substantially all assets, with restrictive covenants and near-term maturities; refinancing or conversion could materially dilute shareholders, with 25.7M shares reserved for convertible-loan conversion vs 37.2M outstanding.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

What to Watch

• AP-SA02 Phase 3: Management targets H2 2026 initiation. FDA concurrence, trial initiation and enrollment would demonstrate progress; further preparation without enrollment would signal delay.
• AP-PA02’s development path: Funding and an agreed next study would show that the mixed Tailwind evidence supports continued investment; prolonged inactivity would leave value increasingly concentrated in AP-SA02.
• Funding beyond preparation: The MTEC award currently runs through 12/31/2026. Further support and financing on sustainable terms would protect development; approaching loan maturities without funding would raise the likelihood of cuts or dilution.